Schwartz-Bartter Syndrome: A Subtle Complication of Small Cell Lung Carcinoma

Brian Boben1, Muhammad Madkour1, Luis Sanguino1* and Marco Viruez2*

Abstract

Paraneoplastic syndromes are defined as a conglomerate of clinical disorders that are caused by neoplastic diseases, specifically lung cancer. The clinical symptomatology of paraneoplastic syndromes usually precedes the diagnosis of the associated neoplasm, however, according to our current literature; the extent of the symptoms is not associated with the size of the tumor. Syndrome of inappropriate anti-diuretic hormone release (SIADH), also known as Schwartz-Bartter syndrome, is commonly caused by small cell lung carcinoma (SCLC) and is characterized by euvolemic hypooosmolar hyponatremia, which will lead to a low serum osmolality as well as a significantly high urine osmolality in the absence of other medical conditions such as adrenal insufficiency, heart failure, cirrhosis, and diuretic syndrome among others. The clinical presentation related to SIADH varies based upon the severity of the hyponatremia as well as the acuteness of the decrease in serum sodium levels. Symptoms due to SIADH include anorexia, nausea, vomiting, and in more severe cases, cerebral edema due to rapid decrease in serum sodium levels. This diagnosis was made after ruling out the other causes of SIADH (pt’s medication record was insignificant). Patient’s euvolemic hypoosmolar hyponatremia was not correctable via fluid restriction or 3% hypertonic saline, and thus a search for a pulmonary source as the culprit was undertaken.

A chest CT revealed a non-specific perihilar mass with numerous enlarged nodes. Subsequently, he underwent a CT guided needle biopsy and was diagnosed with SCLC (Figures 1 and 2). His symptoms progressively got worse with multiple neurological deficits and bone pain. A bone scan showed varying degrees of lytic lesions on the vertebrae. After several discussions with the medical team on his prognosis, patient decided on treatment. The Patient was encouraged to start on Etoposide/Carboplatin combination chemotherapy.

His hyponatremia was closely followed throughout his chemotherapy regimen. Importance was given to the correction rate, which was kept to <8-12 mEq/day to prevent central pontine myelinolysis (CPM). After 2 weeks of chemotherapy, his hyponatremia gradually corrected to a [Na+] of 129 mEq/L. By 10 weeks, it had risen to a stable 135 mEq/L [1,2].

Case Presentation

The Patient is a 65 y/o male with a significant past medical history of HTN and hyperlipidemia who presented to the hospital with a 3-month history of cough associated with hemoptysis, weight loss and fatigue. He admits to a 40-yr pack smoking history and is a frail appearing thin man. He recently made a trip to India, where his symptoms became progressively worse upon returning to the states. Subsequently, upon admission to the hospital, he was found to be negative for TB on quantiferon gamma assay. He worked as an engineer for General Atomics. On physical examination, his vital signs were WNL, except for a significant hyponatremia (Table 1).

Serum Sodium 122 135-145 mEq/L
Urine Sodium 68
Serum Osmolality 299 220-1300
Serum Potassium 3.8 3.5-5.0 mEq/L
Serum Magnesium 2.3 1.5-2.0 mEq/L
Serum Phosphorous 2.3 2.7-4.5 mg/dL

The Patient met the Barter-Schwartz criteria for SIADH (Table 1). This diagnosis was made after ruling out the other causes of SIADH (pt’s medication record was insignificant). Patient’s euvolemic hypoosmolar hyponatremia was not correctable via fluid restriction or 3% hypertonic saline, and thus a search for a pulmonary source as the culprit was undertaken.

A chest CT revealed a non-specific perihilar mass with numerous enlarged nodes. Subsequently, he underwent a CT guided needle biopsy and was diagnosed with SCLC (Figures 1 and 2). His symptoms progressively got worse with multiple neurological deficits and bone pain. A bone scan showed varying degrees of lytic lesions on the vertebrae. After several discussions with the medical team on his prognosis, patient decided on treatment. The Patient was encouraged to start on Etoposide/Carboplatin combination chemotherapy.

His hyponatremia was closely followed throughout his chemotherapy regimen. Importance was given to the correction rate, which was kept to <8-12 mEq/day to prevent central pontine myelinolysis (CPM). After 2 weeks of chemotherapy, his hyponatremia gradually corrected to a [Na+] of 129 mEq/L. By 10 weeks, it had risen to a stable 135 mEq/L [1,2].

Table 1: Patient’s lab values.

Test Results Normal Range
Serum Sodium 122 135-145 mEq/L
Urine Sodium 68
Serum Osmolality 299 220-1300
Serum Potassium 3.8 3.5-5.0 mEq/L
Serum Magnesium 2.3 1.5-2.0 mEq/L
Serum Calcium 8.7 8.4-10.2 mg/dL
Serum Bicarb 22 22-28 mEq/L
Serum Phosphorous 2.3 2.7-4.5 mg/dL

Figure 1: Chest CT scan of right sided SCLC.

*Corresponding author: Luis Sanguino, Graduate Medical Education, California Hospital Medical Center, 1401 S. Grand Avenue, Los Angeles, CA, 90015, USA, Tel: 951-801-0187; E-mail: sanguino001@gmail.com
Marco Viruez, Department of Internal Medicine, California Hospital Medical Center, 1401 S. Grand Avenue, Los Angeles, CA, 90015, USA, Tel: 818-836-9223; E-mail: marcoviruez@dignityhealth.org

Received: December 07, 2017 Accepted: January 10, 2018 Published: January 17, 2018
Discussion

According to the American Cancer Society, lung cancer in 2017 still remains the culprit for being the leading cancer killer in both men and women. SIADH is a disorder of impaired water excretion. ADH (antidiuretic hormone) secretion results in a concentrated urine output and therefore a reduced urine volume. In most patients with SIADH, ingestion of water does not adequately suppress ADH secretion and the urine remains concentrated. This leads to water retention and increased total body water. Subsequently, this lowers the plasma sodium concentration via dilution. Furthermore, the increase in total body water expands the extracellular fluid volume and thus triggers increased urinary sodium excretion; which results in further lowering the plasma sodium concentration. SIADH is best defined by the classic Bartter-Schwartz criteria:

a) Hyponatremia with hypo-osmolality
b) Continued renal excretion of sodium
c) Urine less than maximally dilute
d) Absence of clinical evidence of volume depletion
e) Correction of hyponatremia by fluid restriction

Hyponatremia (Na<135 mmol/L) with associated hypo-osmolality (<280 mOsm/kg), high urine sodium and high urine osmolality are what define SIADH. After excluding other causes of hypo-osmolar hyponatremia (hepatic/cardiac dysfunction, hypothyroidism, cortisol deficiency), then an ectopic source of ADH secretion becomes suspect. The etiology of SIADH is quite diverse, but can be categorized into the following broad categories:

a) Malignancies: Lung (SCLC, Mesothelioma), Brain, GIT (stomach, duodenum, pancreas), GU (bladder, prostate), Lymphomas/Sarcomas
b) Pulmonary disorders: Infections (PNA, TB, Aspergillosis), airway diseases (asthma, COPD, + pressure ventilation)
c) Intracranial: Trauma, stroke, hemorrhage, infection, hydrocephalus, Guillain Barre, MS
d) Drugs: Antipsychotics, chlorpropramide, SSRIs, TCAs, carbamazepine
e) Miscellaneous: Pain, nausea, post-operative state (anesthesia)

SCLC, also known as oat cell carcinoma is a neuroendocrine carcinoma that exhibits aggressive behavior, displays early metastasis, is quite remarkably sensitive to chemotherapy and radiation and is associated with various paraneoplastic syndromes. These include ectopic production of ACTH, Lambert Eaton Myasthenia syndrome and cerebellar sub-acute degeneration caused by Hu, anti-neuronal antibodies (HuAb). These associated syndromes are thought to arise from secretion of peptides, cytokines or hormones from the tumor, and result in inappropriate immune system responses (Figure 3a and 3b).

The correction of SIADH and severe hyponatremia must be handled with extreme care, as acute changes in osmolality significantly affect volume status of cells. The recommended rate of correction is 0.5 mEq/L/hr. The degree of hyponatremia, the patient’s symptoms and the acute VS chronic nature must be taken into consideration.

In our patient, the hyponatremia was chronic, as our patient...
presented with months of fatigue, weight loss and neurological manifestations. During the patient’s extensive work-up, he was found to meet the classic Bartter-Schwartz criteria, and was subsequently diagnosed with SCLC following bronchoscopic biopsy. The patient was given the chemotherapy regimen of Etoposide and Carboplatin, and within a few weeks the patient’s serum sodium levels began to normalize. However, even though the hyponatremia corrected, the patient’s clinical course slowly deteriorated because of the metastasis involving various organs. According to the current literature, hyponatremia due to SIADH is associated with a negative prognostic factor; which is in concordance with our patient. Even though the hyponatremia gradually normalized, the extent of SCLC metastasis was far to advance [3].

Epidemiology

SCLC occurs in 15-20% of lung cancer. SIADH has been reported to occur in approximately 7%-16% of patients with SCLC. Nonetheless, approximately 70% of SIADH cases are reported to be caused by SCLC. The developer of SIADH showed no correlation with clinical stage, distribution of metastatic sites, or histologic subtype of small-cell carcinoma. However, it is reported that patients with hyponatremia due to SIADH have higher mortality rates than patients without it. The incidence and prevalence can range from rates of approximately 25% to 44% if a cut-off point of <136 mEq/L is selected, or rates of approximately 15% if a cut-off point of <130 mEq/L is selected. Thus, the potential for development of clinically significant hyponatremia early in the course of cytotoxic therapy emphasizes the need to closely monitor patients, particularly those receiving chemotherapy regimens requiring substantial intravenous hydration [4].

References


Author Affiliations

1Graduate Medical Education, California Hospital Medical Center, Los Angeles, CA, USA
2Department of Internal Medicine, California Hospital Medical Center, Los Angeles, CA, USA

Submit your next manuscript and get advantages of SciTechnol submissions
- 80 Journals
- 21 Day rapid review process
- 3000 Editorial team
- 5 Million readers
- More than 5000 citations
- Quality and quick review processing through Editorial Manager System

Submit your next manuscript at www.scitechnol.com/submission